Project/Area Number |
11670995
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Osaka University |
Principal Investigator |
HIROYASU Ogawa Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助教授 (80194447)
|
Co-Investigator(Kenkyū-buntansha) |
YUSUKE Oji Osaka University Medical School, Associate Professor, 医学部, 助手 (20294100)
TOSHIHIRO Soma Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助手 (40273619)
YOSHIHIRO Oka Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助手 (20273691)
坪井 昭博 大阪大学, 医学部・附病院, 医員
AKIHIRO Tsuboi Osaka University Hospital, Medical Staff
立川 豊吏 大阪大学, 医学部・附属病院, 医員
|
Project Period (FY) |
1999 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
Keywords | leukemia / minimal residual disease / WT1 / bone marrow transplantation / 微小残存白血病 / キメラ遺伝子 |
Research Abstract |
We have reported that a high expression of WT1 gene is observed in almost all patients with leukemia, and that the detection of minimal residual disease (MRD) can be done in a sensitivity of 10^<-3> to 10^<-5> by the quantitation of WT1 gene expression levels on real-time PCR method. A low level of WT1 gene expression which is observed in CD34+ cells have been found to result in the background level expression of WT1 in bone marrow specimens. In this present study, the background levels of WT1 gene expression was found to reduce in one order in patients after bone marrow transplantation (BMT), by analyzing the WT1 gene expression in bone marrow samples in. which chimeric gene expressions could not be detected in RT-PCR analysis. These findings indicate that the sensitivity to detect MRD was increased after BMT.Furthermore, in the analysis of WT1 levels in patients who underwent BMT, a low level of WT1 gene expression before BMT, the HLA disparity between donors and recipients, and the presence of clinical graft-versus-host disease were found to be good prognostic factors to obtain a continuous complete remission.
|